New progress of myelodysplastic syndromes in the 55th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2014.01.008
- VernacularTitle:第55届美国血液学会年会骨髓增生异常综合征研究领域新进展:5-氮杂胞苷和地西他滨疗效及治疗方案评述
- Author:
Xudong TANG
;
Feng LIU
- Publication Type:Journal Article
- Keywords:
Myelodysplastic syndromes;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2014;23(1):20-21,29
- CountryChina
- Language:Chinese
-
Abstract:
New progress of myelodysplastic syndomes (MDS) in the 55th ASH annual meeting on 5-azacytidine and decitabine was reviewed.Except in older females,the survival time for a diagnosis of MDS in the United States does not seem to have substantially improved since the introduction of 5-azacytidine into the market in 2004.However,clinical and mechanism data suggest that judicious,mechanism-based application and optimization of these agents will have increasingly meaningful impact.Moreover,these drugs are exemplars of an inspiring alternative to the traditional cytotoxic paradigm and should pave the way for additional relatively nontoxic but broadly effective agents.
